Risk stratification of patients with SARS-CoV-2 by tissue factor expression in circulating extracellular vesicles

Burrello, Jacopo; Caporali, Elena; Gauthier, Lorenzo Grazioli; Pianezzi, Enea; Carolina, B. López; Rigamonti, Elia; Bolis, Sara; Lazzarini, Edoardo; Biemmi, Vanessa; Burrello, Alessio; Frigerio, Roberto; Martinetti, Gladys; Fusi-Schmidhauser, Tanja; Vassalli, Giuseppe; Ferrari, Enrico; Moccetti, Tiziano; Gori, Alessandro; Cretich, Marina; Melli, Giorgia; Monticone, Silvia; Barile, Lucio

doi:10.1016/j.vph.2022.106999

Cited by 18 publications

(16 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a correlation between expression of cell surface 51 and extracellular, vesicular 52 CD142 (tissue factor) and COVID-19 disease severity. Interestingly, in a study by Stephenson et al, circulating monocytes displaying the highest levels of ISG expression were found to express ligands and receptors for platelets 59 .…”

Section: Discussionmentioning

confidence: 99%

“…The extrinsic coagulation cascade can be triggered by soluble or cell-surface CD142 (tissue factor). Prior studies have demonstrated increased CD142 expression in the setting of viral infections [49][50][51][52] and in response to LPS 49,53 . In addition, there is a correlation between higher levels of CD142 and COVID-19 disease severity 51,52 .…”

Section: Expression Of Cd142 (Tissue Factor) Is Decreased In Convales...mentioning

confidence: 98%

“…Prior studies have demonstrated increased CD142 expression in the setting of viral infections [49][50][51][52] and in response to LPS 49,53 . In addition, there is a correlation between higher levels of CD142 and COVID-19 disease severity 51,52 . Given the role of coagulopathy in COVID-19 pathogenesis, we wanted to evaluate the expression of CD142 by the various monocyte subsets in our uninfected and convalescent COVID-19 populations.…”

Section: Expression Of Cd142 (Tissue Factor) Is Decreased In Convales...mentioning

confidence: 98%

See 2 more Smart Citations

Reduced Monocyte Proportions and Responsiveness in Convalescent COVID-19 Patients

Ravkov,

Williams,

Elgort

et al. 2023

Preprint

View full text Add to dashboard Cite

The clinical manifestations of acute severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and COVID-19 suggest a dysregulation of the host immune response that leads to inflammation, thrombosis, and organ dysfunction. It is less clear whether these dysregulated processes persist during the convalescent phase of disease or during long COVID. We investigated the effects of SARS-CoV-2 infection on the proportions of classical, intermediate, and non-classical monocytes, their activation status, and their functional properties in convalescent COVID-19 patients and uninfected control subjects. We found that the percentage of total monocytes was decreased in convalescent COVID-19 patients compared to uninfected controls. This was due to decreased intermediate and non-classical monocytes. Classical monocytes from convalescent COVID-19 patients demonstrated a decrease in activation markers, such as CD56, in response to stimulation with bacterial lipopolysaccharide (LPS). In addition, classical monocytes from convalescent COVID-19 patients showed decreased expression of CD142 (tissue factor), which can initiate the extrinsic coagulation cascade, in response to LPS stimulation. Finally, we found that monocytes from convalescent COVID-19 patients produced less TNF-α and IL-6 in response to LPS stimulation, than those from uninfected controls. In conclusion, SARS-CoV-2 infection exhibits a clear effect on the relative proportions of monocyte subsets, the activation status of classical monocytes, and proinflammatory cytokine production that persists during the convalescent phase of disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Expression Of Cd142 (Tissue Factor) Is Decreased In Convales...mentioning

confidence: 98%

Section: Expression Of Cd142 (Tissue Factor) Is Decreased In Convales...mentioning

confidence: 98%

See 1 more Smart Citation

Reduced Monocyte Proportions and Responsiveness in Convalescent COVID-19 Patients

Ravkov,

Williams,

Elgort

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…However, there are certain criteria to be considered when cell-free bodies are used for the treatment. It was found that extracellular vesicles have higher expression of tissue factor CD142 has been correlated to the severity of the infection [122]. CD142 acts as a procoagulant that initiates clotting leading to the systemic inflammatory response [123].…”

Section: Clinical Studies Of Stem Cell-derived Ev or MV Or Exosome-ba...mentioning

confidence: 99%

Pooled evidence from preclinical and clinical studies for stem cell-based therapy in ARDS and COVID-19

Murugan

Rangasamy

2022

Mol Cell Biochem

View full text Add to dashboard Cite

COVID-19 has severely devastated many lives across the globe. It has been speculated that stem cell-based therapy for COVID-19 treatment could be able to subsidize the effects. In preclinical and clinical studies, stem cell-based therapy has successfully eliminated inflammatory cytokines in ALI, ARDS, and COVID-19. Clinical trials have produced a variety of promising results for validating stem cell therapy in COVID-19 patients. For instance, exosome-based therapy (ExoFlow) showed an 87% survival status, and MSC-based therapy (Mesoblast) achieved an 83% survival rate in moderate to severe COVID-19 patients. This review debates the advantages of cell-free therapy, i.e., stem cell-derived exosome-based therapies, over stem cell-based therapy. This review aims to question whether the immunomodulatory effect of stem cells differs based on their origin and also tries to find possible answers for the best stem cells for treating SARS-CoV-2 infection.

show abstract

“…Beyond this initial evidence, it is still unclear how an external chemical and/or physical stimulus changes the content of an exosome or interferes with its release and internalization under physiological and pathological conditions. We cannot ignore, however, that changes in the circulating levels of exosomes can play a theranostic and prognostic key role in patients with cardiovascular diseases, even in those undergoing cardiac surgery [ 12 , 13 , 14 ]; acute lung injury/acute respiratory distress syndrome [ 15 ]; neurodegenerative disorders [ 16 ]; COVID-19 [ 17 ]; and other severe diseases, as summarized in this Special Issue. Levin et al [ 18 ] demonstrated that circulating EVs in patients with beta thalassemia major contain high levels of miR-144-3p, a regulator of erythropoiesis, which leads to the proliferation of bone marrow mesenchymal stem cells and reduced survival of endothelial, pancreatic, and hepatic cells, contributing to the onset of organ dysfunction.…”

mentioning

confidence: 99%

The Role of Exosomes in Health and Disease

Lionetti

2022

IJMS

View full text Add to dashboard Cite

show abstract

Risk stratification of patients with SARS-CoV-2 by tissue factor expression in circulating extracellular vesicles

Cited by 18 publications

References 36 publications

Reduced Monocyte Proportions and Responsiveness in Convalescent COVID-19 Patients

Reduced Monocyte Proportions and Responsiveness in Convalescent COVID-19 Patients

Pooled evidence from preclinical and clinical studies for stem cell-based therapy in ARDS and COVID-19

The Role of Exosomes in Health and Disease

Contact Info

Product

Resources

About